Alkeus Pharmaceuticals Announces Positive Gildeuretinol Data Will Be Presented During the 12th International FLORetina ICOOR Congress December 5–8 in Florence, Italy
05 déc. 2024 08h30 HE
|
Alkeus Pharmaceuticals
CAMBRIDGE, Mass., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc. today announced that results from its clinical studies of investigational oral gildeuretinol for the treatment of...
Alkeus Pharmaceuticals Receives FDA Rare Pediatric Disease and Fast Track Designations for Gildeuretinol as a Treatment for Stargardt Disease
18 nov. 2024 09h16 HE
|
Alkeus Pharmaceuticals
Alkeus Pharmaceuticals, Inc. receives FDA Rare Pediatric Disease and Fast Track designations for gildeuretinol as a treatment for Stargardt Disease
Alkeus Pharmaceuticals Appoints David Arkowitz as Chief Financial Officer
31 oct. 2024 08h30 HE
|
Alkeus Pharmaceuticals
Alkeus Pharmaceuticals appoints David Arkowitz as Chief Financial Officer.
Topline Results from Alkeus Pharmaceuticals’ Study of Oral Gildeuretinol Demonstrate Significant Trend in Slowing GA Progression and Visual Function Improvement
23 oct. 2024 09h00 HE
|
Alkeus Pharmaceuticals
Alkeus Pharmaceuticals, Inc., today announced that results from its study of gildeuretinol in geographic atrophy were presented at AAO 2024.
Alkeus Pharmaceuticals Announces Data Presentations at the American Academy of Ophthalmology (AAO) 2024 Annual Meeting, October 18-21 in Chicago
17 oct. 2024 08h29 HE
|
Alkeus Pharmaceuticals
Results from Study of Oral Gildeuretinol for Geographic Atrophy Secondary to Age-Related Macular Degeneration to be Presented as Late-Breaker During Retina Subspecialty Day Positive Data from TEASE...
Alkeus Pharmaceuticals Announces Results from the SAGA Study of Oral Gildeuretinol in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
17 sept. 2024 08h30 HE
|
Alkeus Pharmaceuticals
Oral gildeuretinol demonstrated a clinically meaningful reduction in the geographic atrophy (GA) lesion growth rate at 24 months, supporting further clinical development.Gildeuretinol showed a...
Alkeus Pharmaceuticals Announces Presentation of a TEASE-3 Study Update Showing Progression Stalled in Early-Stage Stargardt Disease Patients Treated with Gildeuretinol
18 juil. 2024 10h20 HE
|
Alkeus Pharmaceuticals
Alkeus Pharmaceuticals announces presentation of a TEASE-3 study update showing progression stalled in early-stage Stargardt disease
Alkeus Pharmaceuticals Appoints Tamara Dillon as Chief Human Resources Officer
16 juil. 2024 09h00 HE
|
Alkeus Pharmaceuticals
Alkeus Pharmaceuticals appoints Tamara Dillon as Chief Human Resources Officer
Accomplished Biotech Leader Michel Dahan Joins Alkeus as President and CEO
02 juil. 2024 08h30 HE
|
Alkeus Pharmaceuticals
Alkeus Pharmaceuticals, Inc. announced today that Michel Dahan has joined the company as President and Chief Executive Officer.
Alkeus Pharmaceuticals Appoints Eric L. Trachtenberg as Chief Legal Officer
29 mai 2024 09h00 HE
|
Alkeus Pharmaceuticals
Alkeus Pharmaceuticals, Inc. today announced that Eric L. Trachtenberg, J.D., M.B.A., has joined the company as Chief Legal Officer.